Systematic review of the use and value of computer simulation modelling in population health and health care delivery

Journal of Public Health Medicine

Volumn 25, Issue 4, 2003, Pages 325-335

  Fone, David ^a,b,f,g,i   Hollinghurst, Sandra ^a   Temple, Mark ^c,f   Round, Alison ^b,d,f   Lester, Nathan ^a   Weightman, Alison ^b,h   Roberts, Katherine ^b,h   Coyle, Edward ^a   Bevan, Gwyn ^e   Palmer, Stephen ^b,g  

^a ANEURIN BEVAN UNIVERSITY HEALTH BOARD   (United Kingdom)

^b CARDIFF UNIVERSITY   (United Kingdom)

^c Bro Taf Health Authority   (United Kingdom)

^d N and E Devon Health Authority   (United Kingdom)

^e LONDON SCHOOL OF ECONOMICS   (United Kingdom)

^f Public Health Medicine   (United Kingdom)

^g Dept of Epidemiol and Pub Health ^*  (United Kingdom)

^h Library Services   (United States)

ⁱ PUBLIC HEALTH WALES   (United Kingdom)

Author keywords

Health care; Simulation modelling; Systematic review

Indexed keywords

COMMUNICABLE DISEASE; COMPUTER SIMULATION; DATA BASE; EMBASE; HEALTH CARE COST; HEALTH CARE DELIVERY; HEALTH CARE POLICY; HEALTH STATUS; HUMAN; MASS SCREENING; MEDLINE; PRIORITY JOURNAL; QUALITY CONTROL; REVIEW; SCISEARCH; STOCHASTIC MODEL;

COMMUNICABLE DISEASE CONTROL; COMPUTER SIMULATION; COSTS AND COST ANALYSIS; DELIVERY OF HEALTH CARE; MASS SCREENING; MODELS, STATISTICAL; PERSONNEL STAFFING AND SCHEDULING; RESEARCH DESIGN; STOCHASTIC PROCESSES;

EID: 10744220534     PISSN: 09574832     EISSN: None     Source Type: Journal    
DOI: 10.1093/pubmed/fdg075     Document Type: Review

References (67)

1. Royston G. Commentary: trials versus models in appraising screening programmes. Br Med J 1999; 318: 360-361.
2. Taylor K, Lane D. Simulation applied to health services: opportunities for applying the system dynamics approach. J Hlth Serv Res Policy 1998; 3: 226-232.
3. Temple JMF, Fone DL. Implementing national guidance on prevention of coronary heart disease: clinical governance and computer simulation modelling. Br J Clin Gov 2002; 7(1): 27-33.
4. Davies R. An assessment of models of a health system. J Op Res Soc 1985; 36(8): 679-686.
5. Lehaney B, Hlupic V. Simulation modelling for resource allocation and planning in the health sector. JR Soc Hlth 1995; 115(6): 382-385.
6. Jun JB, Jacobson SH, Swisher JR. Applications of discrete-event simulation in health care clinics: a survey. J Op Res Soc 1999; 50(2): 109-123.
7. National Research Register 1999, Issue 4. [On-line.] Available at http://www.doh.gov.uk/research/nrr.htm (6 October 2003, date last accessed).
8. Weightman AL, Barker J, Lancaster J. Health Evidence Bulletins-Wales: a methodical approach to identifying the evidence. Project methodology 4. Cardiff: University of Wales College of Medicine, Department of Information Services, 2001. [On-line.] Available at http://hebw.uwcm.ac.uk/projectmethod/title.htm (6 October 2003, date last accessed).
9. Mulrow CD, Oxman AD, eds. The Cochrane Collaboration Handbook Version 4. 0 (Updated 1 March 1997). In: The Cochrane Library. Oxford: The Cochrane Collaboration, 1996.
10. Stafford EF Jr, Aggarwal SC. Managerial analysis and decision-making in outpatient health clinics. J Op Res Soc 1979; 30: 905-915.
11. Reilly TA, Marathe VP, Fries BE. A delay-scheduling model for patients using a walk-in clinic. J Med Sys 1978; 2: 303-313.
12. Dexter F, Macario A, Traub RD, Hopwood M, Lubarsky DA. An operating room scheduling strategy to maximize the use of operating room block time: computer simulation of patient scheduling and survey of patients' preferences for surgical waiting time. Anaes Analg 1999; 89: 7-20.
13. Fitzpatrick KE, Baker JR, Dave DS. An application of computer simulation to improve scheduling of hospital operating room facilities in the United States. Int J Comp Apps Tech 1993; 6: 205-224.
14. Dittus RS, Klein RW, DeBrota DJ, Dame MA, Fitzgerald JF. Medical resident work schedules: design and evaluation by simulation modelling. Man Sci 1996; 42: 891-906.
15. Hendershott TH. Evaluating process change proposals in an outpatient pharmacy using simulation. Proc Hlth Inform Manage Syst Soc 1996; 165-174.
16. Vemuri S. Simulated analysis of patient waiting time in an outpatient pharmacy. Am J Hosp Pharm 1984; 41: 1127-1130.
17. Taylor BW, Keown AJ. A network analysis of an inpatient/outpatient department. J Op Res Soc 1980; 31: 169-179.
18. Hirshberg A, Stein M, Walden R. Surgical resource utilization in urban terrorist bombing: a computer simulation. J Trauma-Injury Infect Crit Care 1999; 47: 545-550.
19. Altinel IK, Ulas E. Simulation modeling for emergency bed requirement planning. Ann Op Res 1996; 67: 183-210.
20. Vassilacopoulos G. A simulation model for bed allocation to hospital inpatient departments. Simulation 1985; 45: 233-241.
21. Cohen MA, Hershey JC, Weiss EN. Analysis of capacity decisions for progressive patient care hospital facilities. Hlth Serv Res 1980; 15: 145-160.
22. Goldberg J, Dietrich R, Chen JM, et al. A simulation model for evaluating a set of emergency vehicle base locations: development, validation, and usage. Soc Econ Plan Sci 1990; 24: 125-141.
23. Auvert B, Moore M, Bertrand WE, et al. Dynamics of HIV infection and AIDS in central African cities. Int J Epidemiol 1990; 19: 417-428.
24. Kretzschmar M, van Duynhoven YT, Severijnen AJ. Modeling prevention strategies for gonorrhea and chlamydia using stochastic network simulations. Am J Epidemiol 1996; 144: 306-317.
25. Nourjah P, Frerichs RR. Minimum attack rate for measuring measles vaccine efficacy. Int J Epidemiol 1995; 24: 834-841.
26. De Boo ThM, Van Druten JAM, Plantinga AD. Predicting the dynamic effects of rubella vaccination programmes. Statist Med 1987; 6: 843-851.
27. Sebille V, Valleron AJ. A computer simulation model for the spread of nosocomial infections caused by multidrug-resistant pathogens. Comp Biomed Res 1997; 30: 307-322.
28. Eastman RC, Javitt JC, Herman WH, et al. Model of complications of NIDDM. I. Model construction and assumptions. Diab Care 1997; 20: 725-734.
29. Eastman RC, Javitt JC, Herman WH, et al. Model of complications of NIDDM. II. Analysis of the health benefits and cost-effectiveness of treating NIDDM with the goal of normoglycemia. Diab Care 1997; 20: 735-744.
30. Nathan DM. Lifetime benefits and costs of intensive therapy as practiced in the diabetes control and complications trial. JAMA 1996; 276: 1409-1415.
31. Ramsdell JW, Grossman JA, Stephens JM, Botteman MF, Arocho R. A short-term cost-of-treatment model for type 2 diabetes: comparison of glipizide gastrointestinal therapeutic system, metformin, and acarbose. Am J Man Care 1999; 5: 1007-1024.
32. Roberts SD, Maxwell DR, Gross TL. Cost-effective care of end-stage renal disease: a billion dollar question. Ann Int Med 1980; 92: 243-248.
33. McHugh ML. Cost-effectiveness of clustered unit vs. unclustered nurse floating. Nurse Econ 1997; 15: 294-300.
34. van Ballegooijen M, Koopmanschap MA, van Oortmarssen GJ, et al. Diagnostic and treatment procedures induced by cervical cancer screening. Eur J Cancer 1990; 26: 941-945.
35. Koopmanschap MA, van Oortmarssen GJ, van Agt HM, et al. Cervical-cancer screening: attendance and cost-effectiveness. Int J Cancer 1990; 45: 410-415.
36. van Ballegooijen M, Habbema JD, van Oortmarssen GJ, et al. Preventive pap-smears: balancing costs, risks and benefits. Br J Cancer 1992; 65: 930-933.
37. van Ballegooijen M, van den Akker-van Marle ME, Warmerdam PG, et al. Present evidence on the value of HPV testing for cervical cancer screening: a model-based exploration of the cost-effectiveness. Br J Cancer 1997; 76: 651-657.
38. van der Maas PJ, de Koning HJ, van Ineveld BM, et al. The cost-effectiveness of breast cancer screening. Int J Canc 1989; 43: 1055-1060.
39. de Koning HJ, Boer R, Warmerdam PG, Beemsterboer PM, van der Maas PJ. Quantitative interpretation of age-specific mortality reductions from the Swedish breast cancer-screening trials. J Nat Cancer Inst 1995; 87: 1217-1223.
40. de Koning HJ, van Ineveld BM, van Oortmarssen GJ, et al. Breast cancer screening and cost-effectiveness; policy alternatives, quality of life considerations and the possible impact of uncertain factors. Int J Cancer 1991; 49: 531-537.
41. de Haes JC, de Koning HJ, van Oortmarssen GJ, et al. The impact of a breast cancer screening programme on quality-adjusted-life-years. Int J Cancer 1991; 49: 538-544.
42. Boer R, de Koning HJ, van Oortmarssen GJ, van der Maas PJ. In search of the best upper age limit for breast cancer screening. Eur J Cancer 1995; 31A: 2040-2043.
43. Boer R, de Koning HJ, van der Maas PJ. A longer breast carcinoma screening interval for women aged older than 65 years. Cancer 1999; 86: 1506-1510.
44. van Ineveld BM, van Oortmarssen GJ, de Koning HJ, Boer R, van der Maas PJ. How cost-effective is breast cancer screening in different EC countries? Eur J Cancer 1993; 29A: 1663-1668.
45. Carter DM, Glasziou P, van Oortmarssen GJ, et al. Cost-effectiveness of mammographic screening in Australia. Aust NZ J Publ Hlth 1993; 17: 42-50.
46. Beemsterboer PM, de Koning HJ, Warmerdam PG, et al. Prediction of the effects and costs of breast cancer screening in Germany. Int J Cancer 1994; 58: 623-628.
47. Warmerdam PG, de Koning HJ, Boer R, et al. Quantitative estimates of the impact of sensitivity and specificity in mammographic screening in Germany. J Epidemiol Commun Hlth 1997; 51: 180-186.
48. Paci E, Boer R, Zappa M, et al. A model-based prediction of the impact on reduction in mortality by a breast cancer screening programme in the city of Florence, Italy. Eur J Cancer 1995; 31A: 348-353.
49. van den Akker-van Marle ME, Reep-van den Bergh CM, Boer R, et al. Breast cancer screening in Navarra: interpretation of a high detection rate at the first screening round and a low rate at the second round. Int J Cancer 1997; 73: 464-469.
50. Beemsterboer PMM, Warmerdam PG, Boer R, et al. Screening for breast cancer in Catalonia: which policy is to be preferred? Eur J Publ Hlth 1998; 8: 241-246.
51. Szeto KL, Devlin NJ. The cost-effectiveness of mammography screening: evidence from a microsimulation model for New Zealand. Hlth Pol 1996; 38: 101-115.
52. van den Akker-van Marle ME, de Koning HJ, Boer R, van der Maas PJ. Reduction in breast cancer mortality due to the introduction of mass screening in the Netherlands; comparison with the United Kingdom. J Med Screen 1999; 6: 30-34.
53. Loeve F, Boer R, van Oortmarssen GJ, van Ballegooijen M, Habbema JD. The MISCAN-COLON simulation model for the evaluation of colorectal cancer screening. Comp Biomed Res 1999; 32: 13-33.
54. Skates SJ, Singer DE. Quantifying the potential benefit of CA 125 screening for ovarian cancer. J Clin Epidemiol 1991; 44: 365-380.
55. Urban N, Drescher C, Etzioni R, Colby C. Use of a stochastic simulation model to identify an efficient protocol for ovarian cancer screening. Cont Clin Trials 1997; 18: 251-270.
56. Parkin DM, Moss SM. An evaluation of screening policies for cervical cancer in England and Wales using a computer simulation model. J Epidemiol Commun Hlth 1986; 40: 143-153.
57. Javitt JC, Canner JK, Sommer A. Cost effectiveness of current approaches to the control of retinopathy in type I diabetics. Ophthalm 1989; 96: 255-264.
58. Fendrick AM, McCort JT, Chernew ME, et al. Immediate eradication of Helicobacterpylori in patients with previously documented peptic ulcer disease: clinical and economic effects. Am J Gastroent 1997; 92: 2017-2024.
59. Javitt JC, Canner JK, Frank RG, Steinwachs DM, Sommer A. Detecting and treating retinopathy in patients with Type I diabetes mellitus. Ophthalmologica 1990; 97: 483-495.
60. Javitt JC, Aiello LP, Bassi LJ, Chiang YP, Canner JK. Detecting and treating retinopathy in patients with type I diabetes mellitus. Savings associated with improved implementation of current guidelines. American Academy of Ophthalmology. Ophthalmologica 1991; 98: 1565-1573.
61. Javitt JC, Dei CR, Chiang YP. Cost-effectiveness of screening and cryotherapy for threshold retinopathy of prematurity. Pediatrics 1993; 91: 859-866.
62. Javitt JC, Aiello LP, Chiang Y, et al. Preventive eye care in people with diabetes is cost-saving to the federal government. Implications for health-care reform. Diab Care 1994; 17: 909-917.
63. Javitt JC, Aiello LP. Cost-effectiveness of detecting and treating diabetic retinopathy. Ann Int Med 1996; 124: 164-169.
64. Bronnum-Hansen H. How good is the Prevent model for estimating the health benefits of prevention? J Epidemiol Commun Hlth 1999; 53: 300-305.
65. Warner KE, Smith RJ, Smith DG, Fries BE. Health and economic implications of a work-site smoking-cessation program: a simulation analysis. J Occup Environ Med 1996; 38: 981-992.
66. Zenios SA, Wein LM, Chertow GM. Evidence-based organ allocation. Am J Med 1999; 107: 52-61.
67. Public Health Resource Unit, Oxford Critical Appraisal Skills Programme. Learning resources appraisal tools [On-line.] Available at http://www.phru.org.uk/~casp/appraisal.htm (6 October 2003, date last accessed).